83 FR 55557 - National Heart, Lung, and Blood Institute; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 215 (November 6, 2018)

Page Range		55557-55557
FR Document		2018-24222

Federal Register, Volume 83 Issue 215 (Tuesday, November 6, 2018)

[Federal Register Volume 83, Number 215 (Tuesday, November 6, 2018)]
[Notices]
[Page 55557]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-24222]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel Review of NHLBI Cardiac Surgery Network 
Coordinating Center.
    Date: November 26, 2018.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Shelley S Sehnert, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD 
20892-7924, 301-435-0303, [email protected].

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel NHLBI SBIR Phase IIB Bridge Awards.
    Date: November 27, 2018.
    Time: 7:30 a.m. to 9:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: Crowne Plaza, Washington National Airport, 1489 Jefferson 
Davis Hwy, Arlington, VA 22202.
    Contact Person: William J Johnson, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6701 Rockledge Drive, Room 7178, Bethesda, MD 
20892-7924, 301-827-7938, [email protected].

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel NHLBI SBIR Phase IIB Small Market Awards.
    Date: November 27, 2018.
    Time: 9:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Crowne Plaza, Washington National Airport, 1489 Jefferson 
Davis Hwy, Arlington, VA 22202.
    Contact Person: William J Johnson, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6701 Rockledge Drive, Room 7178, Bethesda, MD 
20892-7924, 301-827-7938, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: October 31, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-24222 Filed 11-5-18; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 215 / Tuesday, November 6, 2018 / Notices 55557

SUMMARY: The National Heart, Lung and development of obesity and its 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Blood Institute (NHLBI), National metabolic consequences, including as amended. The grant applications and
Institutes of Health, Department of insulin resistance and type 2 diabetes. the discussions could disclose
Health and Human Services, is Beta-cell loss has been demonstrated in confidential trade secrets or commercial
contemplating the grant of an exclusive a Zucker diabetic fatty (ZDF) rat model property such as patentable material,
commercialization patent license to of type-2 diabetes through CB1R- and personal information concerning
Ovensa, Inc. headquartered in Ontario, mediated activation of a macrophage- individuals associated with the grant
Canada, to practice the inventions mediated inflammatory response. applications, the disclosure of which
embodied in the patent application(s) Conversely, rats treated with a would constitute a clearly unwarranted
listed in the Supplementary Information peripheral CB1R antagonist restores invasion of personal privacy.
section of this notice. normoglycemia and preserves beta-cell Name of Committee: National Heart, Lung,
DATES: Only written comments and/or function. Similar results are seen and Blood Institute Special Emphasis Panel
applications for a license which are following selective in vivo knockdown Review of NHLBI Cardiac Surgery Network
received by the NHLBI Office of of macrophage CB1R by daily treatment Coordinating Center.
Technology Transfer and Development of ZDF rats with the instant D-glucan- Date: November 26, 2018.
November 21, 2018 will be considered. encapsulated CB1R small interfering Time: 1:00 p.m. to 3:00 p.m.
ADDRESSES: Requests for copies of the RNA (siRNA). Knock-down of CB1R Agenda: To review and evaluate grant
using glucan encapsulated siRNA applications.
patent applications, inquiries, and
Place: National Institutes of Health, 6701
comments relating to the contemplated represent new methods of treating type-
Rockledge Drive, Bethesda, MD 20892
exclusive patent license should be 2 diabetes or preventing the progression (Telephone Conference Call).
directed to: Michael Shmilovich, Esq., of insulin resistance to overt diabetes. Contact Person: Shelley S Sehnert, Ph.D.,
Senior Licensing and Patent Manager, This notice is made in accordance Scientific Review Officer, Office of Scientific
31 Center Drive, Room 4A29, MSC2479, with 35 U.S.C. 209 and 37 CFR part 404. Review/DERA, National Heart, Lung, and
Bethesda, MD 20892–2479, phone The prospective exclusive patent license Blood Institute, 6701 Rockledge Drive, Room
number 301–435–5019, or shmilovm@ will be royalty bearing and may be 7206, Bethesda, MD 20892–7924, 301–435–
mail.nih.gov. granted unless within fifteen (15) days 0303, ssehnert@nhlbi.nih.gov.
SUPPLEMENTARY INFORMATION: The
from the date of this published notice, Name of Committee: National Heart, Lung,
following and all continuing U.S. and the NHLBI receives written evidence and Blood Institute Special Emphasis Panel
and argument that establishes that the NHLBI SBIR Phase IIB Bridge Awards.
foreign patents/patent applications Date: November 27, 2018.
thereof are the intellectual properties to grant of the license would not be
consistent with the requirements of 35 Time: 7:30 a.m. to 9:30 a.m.
be licensed under the prospective Agenda: To review and evaluate grant
agreement to Ovensa: HHS Ref. No. E– U.S.C. 209 and 37 CFR part 404. applications.
103–2013–0, U.S. Provisional Patent Complete applications for a license in Place: Crowne Plaza, Washington National
Application 61/839,239, ‘‘Glucan- the prospective field of use that are Airport, 1489 Jefferson Davis Hwy, Arlington,
Encapsulated siRNA For Treating Type timely filed in response to this notice VA 22202.
2 Diabetes Mellitus,’’ filed June 25, will be treated as objections to the grant Contact Person: William J Johnson, Ph.D.,
2013, International Patent Application of the contemplated exclusive patent Scientific Review Officer, Office of Scientific
license. Review/DERA, National Heart, Lung, and
PCT/2014/043924 filed June 24, 2014, Blood Institute, 6701 Rockledge Drive, Room
European Patent Application Comments and objections submitted
to this notice will not be made available 7178, Bethesda, MD 20892–7924, 301–827–
14818342.9 filed June 24, 2018, and US 7938, johnsonwj@nhlbi.nih.gov.
Patent 10,077,446 filed June 24, 2014 for public inspection and, to the extent
permitted by law, will not be released Name of Committee: National Heart, Lung,
and issued September 18, 2018. The and Blood Institute Special Emphasis Panel
patent rights in this invention have been under the Freedom of Information Act,
NHLBI SBIR Phase IIB Small Market Awards.
assigned to the Government of the 5 U.S.C. 552. Date: November 27, 2018.
United States of America. The Dated: October 24, 2018. Time: 9:30 a.m. to 5:00 p.m.
prospective license would be granted Michael A. Shmilovich, Agenda: To review and evaluate grant
worldwide and in a field of use not Senior Licensing and Patenting Manager, applications.
broader than therapeutics for preventing National Heart, Lung, and Blood Institute, Place: Crowne Plaza, Washington National
Office of Technology Transfer and Airport, 1489 Jefferson Davis Hwy, Arlington,
or treating insulin resistance and non- VA 22202.
alcoholic fatty liver disease/non- Development.
Contact Person: William J Johnson, Ph.D.,
alcoholic steatohepatitis. The scope of [FR Doc. 2018–24225 Filed 11–5–18; 8:45 am] Scientific Review Officer, Office of Scientific
any proposed licensed may also be BILLING CODE 4140–01–P Review/DERA, National Heart, Lung, and
limited to products sold that include Blood Institute, 6701 Rockledge Drive, Room
therapeutic siRNAs encapsulated in 7178, Bethesda, MD 20892–7924, 301–827–
nanoparticles made from either glucan DEPARTMENT OF HEALTH AND 7938, johnsonwj@nhlbi.nih.gov.
based biopolymers and/or Ovensa’s HUMAN SERVICES (Catalogue of Federal Domestic Assistance
TRIOZANTM (N,N,N-Trimethyl Program Nos. 93.233, National Center for
Chitosan) proprietary biopolymer. National Institutes of Health Sleep Disorders Research; 93.837, Heart and
The invention pertains to the use of Vascular Diseases Research; 93.838, Lung
National Heart, Lung, and Blood Diseases Research; 93.839, Blood Diseases
glucan encapsulated non-
Institute; Notice of Closed Meetings and Resources Research, National Institutes
immunostimulatory small interfering
khammond on DSK30JT082PROD with NOTICES

of Health, HHS)
RNAs (siRNAs) to treat type-2 diabetes. Pursuant to section 10(d) of the
Endocannabinoids (EC) are lipid Federal Advisory Committee Act, as Dated: October 31, 2018.
signaling molecules that act on the same amended, notice is hereby given of the Ronald J. Livingston, Jr.,
cannabinoid receptors that recognize following meetings. Program Analyst, Office of Federal Advisory
and mediate the effects of endo- and The meetings will be closed to the Committee Policy.
phytocannabanoids. EC receptor CB1R public in accordance with the [FR Doc. 2018–24222 Filed 11–5–18; 8:45 am]
activation is implicated in the provisions set forth in sections BILLING CODE 4140–01–P

VerDate Sep<11>2014 17:05 Nov 05, 2018 Jkt 247001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\06NON1.SGM 06NON1

Document Created: 2018-11-06 00:18:28
Document Modified: 2018-11-06 00:18:28

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		November 26, 2018.
FR Citation		83 FR 55557

83 FR 55557 - National Heart, Lung, and Blood Institute; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 215 (November 6, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health